NCT07263191 A Study of Olanzapine in Participants With Bipolar Disorder.
| NCT ID | NCT07263191 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Condition | Bipolar Disorder |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2025-10-30 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2025-10-30 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aimed to identify treatment patterns in patients with bipolar disorder receiving olanzapine according to demographic and clinical characteristics and to evaluate the effectiveness of education on weight gain, a side effect of olanzapine, in preventing weight gain.
Eligibility Criteria
Inclusion Criteria: * Patients who have signed the informed consent after receiving information about the purpose and method of this study. * Patients diagnosed with bipolar disorder and scheduled to receive olanzapine. * Patients who understand the contents of the survey and can answer the questions directly. Exclusion Criteria: * Female patients who are pregnant, have childbearing potential, or are breastfeeding. * Has received an investigational product within 12 weeks from the study enrollment or has plans to participate in another clinical trial during the participation of this study. * Other subjects who are considered inappropriate to participate in this study by the judgment of the investigator.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07263191 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Bipolar Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07263191 currently recruiting?
Yes, NCT07263191 is actively recruiting participants. Contact the research team at syoh@boryung.co.kr for enrollment information.
Where is the NCT07263191 trial being conducted?
This trial is being conducted at Seongnam, South Korea.
Who is sponsoring the NCT07263191 clinical trial?
NCT07263191 is sponsored by Boryung Pharmaceutical Co., Ltd. The trial plans to enroll 3,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.